Advertisement
COO vs DXR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Hold and DXR is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 1 FA rating(s) are green whileDXR’s FA Score has 0 green FA rating(s).
- COO’s FA Score: 1 green, 4 red.
- DXR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 5 TA indicator(s) are bullish while DXR’s TA Score has 3 bullish TA indicator(s).
- COO’s TA Score: 5 bullish, 4 bearish.
- DXR’s TA Score: 3 bullish, 6 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а -1.77% price change this week, while DXR (@Pharmaceuticals: Other) price change was +1.45% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.32%. For the same industry, the average monthly price growth was -1.03%, and the average quarterly price growth was -14.58%.
Reported Earning Dates
COO is expected to report earnings on Sep 02, 2026.
DXR is expected to report earnings on Aug 20, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.32% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| COO | DXR | COO / DXR | |
| Capitalization | 12.9B | 59.2M | 21,791% |
| EBITDA | 1.08B | N/A | - |
| Gain YTD | -20.181 | -35.593 | 57% |
| P/E Ratio | 55.44 | 5.79 | 957% |
| Revenue | 4.15B | 10.3M | 40,311% |
| Total Cash | 125M | N/A | - |
| Total Debt | 2.5B | 263K | 950,570% |
COO | DXR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 86 | 42 | |
PRICE GROWTH RATING 1..100 | 59 | 63 | |
P/E GROWTH RATING 1..100 | 14 | 100 | |
SEASONALITY SCORE 1..100 | 46 | 12 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COO's Valuation (72) in the Medical Specialties industry is in the same range as DXR (76). This means that COO’s stock grew similarly to DXR’s over the last 12 months.
COO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXR (100). This means that COO’s stock grew similarly to DXR’s over the last 12 months.
DXR's SMR Rating (42) in the Medical Specialties industry is somewhat better than the same rating for COO (86). This means that DXR’s stock grew somewhat faster than COO’s over the last 12 months.
COO's Price Growth Rating (59) in the Medical Specialties industry is in the same range as DXR (63). This means that COO’s stock grew similarly to DXR’s over the last 12 months.
COO's P/E Growth Rating (14) in the Medical Specialties industry is significantly better than the same rating for DXR (100). This means that COO’s stock grew significantly faster than DXR’s over the last 12 months.
| COO | DXR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | N/A |
| Stochastic ODDS (%) | 2 days ago 55% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 72% |
| MACD ODDS (%) | N/A | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 49% | 2 days ago 72% |
| Advances ODDS (%) | 19 days ago 57% | 8 days ago 68% |
| Declines ODDS (%) | 8 days ago 60% | 14 days ago 73% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 50% | 2 days ago 84% |
Advertisement
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.
DXR and
Correlation & Price change
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | -2.56% | ||
| IART - DXR | 33% Poorly correlated | +0.11% | ||
| BWAY - DXR | 27% Poorly correlated | -3.02% | ||
| AVTR - DXR | 23% Poorly correlated | -2.40% | ||
| COO - DXR | 20% Poorly correlated | -0.74% | ||
| SHC - DXR | 20% Poorly correlated | -0.54% | ||
More | ||||